Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NGENF NERVGEN PHARMA CORP

Watchlist
1.330
+0.030+2.31%
Close  12/06 16:00 ET
High
1.336
Open
1.336
Turnover
17.03K
Low
1.320
Pre Close
1.300
Volume
12.83K
Market Cap
78.04M
P/E(TTM)
Loss
52wk High
2.540
Shares
58.68M
P/E(Static)
Loss
52wk Low
1.100
Float Cap
78.04M
Bid/Ask %
0.00%
Historical High
2.670
Shs Float
58.68M
Volume Ratio
0.45
Historical Low
1.050
Dividend TTM
--
Div Yield TTM
--
P/B
5.71
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.02%
Amplitude
1.22%
Avg Price
1.327
Lot Size
1
Float Cap
78.04M
Bid/Ask %
0.00%
Historical High
2.670
Shs Float
58.68M
Volume Ratio
0.45
Historical Low
1.050
Dividend TTM
--
P/B
5.71
Dividend LFY
--
Turnover Ratio
0.02%
Amplitude
1.22%
Avg Price
1.327
Lot Size
1
Price Forecast

News

Comment

Sign in to post a comment

    No comment yet

    Company Overview More
    NervGen Pharma Corp. operates as a regenerative medicine company engaged in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was founded by Brian J. McAlister and William Joseph Radvakon January 19, 2017 and is headquartered in Vancouver, Canada.
    CEO: Mr. Paul Brennan
    Market: Pink Market
    Hot List
    TradeSearchNews
    SymbolLatest price%Chg

    Loading...

    Watchlist